Humacyte presented long-term results from a humanitarian program conducted in Ukraine under which the investigational acellular tissue engineered vessel was used to treat vascular injuries suffered during the ongoing conflict. Long-term follow-up results were presented for the first time and showed high rates of patency and the avoidance of amputation and infection despite the severe nature of the wartime injuries treated. The results were presented at the Military Health System Research Symposium, the U.S. Department of Defense’s foremost scientific meeting, held in Kissimmee, Florida. The presentation highlighted the results for 16 extremity patients treated in Ukraine who provided consent for use of their results, a set of data known as the “V017 trial.” The primary analyses for the V017 trial were at 30 days of follow up, and as previously reported the rate of success for treatment of patients with the ATEV at this time point was high with primary and secondary patency of 93.8%, zero amputations, and zero cases of infection of the ATEV. Longer-term results for the V017 patients were presented for the first time at the MHSRS meeting, with a mean follow-up duration of 357.9 days. Kaplan-Meier estimates of 12-month primary and secondary patency both were 87.1%. There were no instances of ATEV infections, amputation of affected limbs, or deaths related to ATEV through the end of long-term follow-up. There was one event of ATEV thrombosis after month six. There were no reports of ATEV aneurysm or pseudo-aneurysm. These results were achieved despite the fact that all patients had a high risk of wound infection and were severely injured, with a mean Injury Severity Score (ISS) of 20.1. Patients treated with the ATEV included those injured due to mine blasts, shrapnel and high velocity ballistics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program
- Small Cap Stocks: FDA Delay Created Buy-On-The-Dip Opportunity for Humacyte (HUMA)
- Humacyte reports Q2 EPS (48c) , consensus (24c)
- Texas probes CenterPoint, Carlyle weighs Nobian sale: Monday Buzz
- Humacyte drops 17% as FDA needs more time for ATEV review
Questions or Comments about the article? Write to editor@tipranks.com